Despite the fact that the in vitro investigation reveals outstanding AG inhibitory activity, in vivo studies are necessary to determine the therapeutic potential of these molecules before they can be considered for the treatment of T2DM. Here, RENBP is linked to type 2 diabetes mellitus.